This document is a published patent application (US20260083782A1) from the USPTO, filed on September 23, 2024. It describes a novel application of Micrococcus porci, or its lysates, cultures, or extracts, as an active ingredient in antimicrobial compositions. These compositions exhibit selective activity against harmful Staphylococcus species, including Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus capitis.

The implications for regulated entities are primarily related to intellectual property and potential future product development. Companies in the pharmaceutical, cosmetic, and quasi-drug sectors may need to assess this patent filing for potential conflicts with their own research or product lines. While this is a patent application and not a regulatory rule, it signifies a new area of innovation that could lead to future regulatory considerations for products incorporating this technology. No immediate compliance actions are required based solely on this patent publication.